mTOR inhibition in management of advanced breast cancer

The mTOR pathway is becoming increasingly important in several cancers including breast cancer. This review will focus on the role of its inhibition in the management of advanced breast cancer.

• Publication year

  2012

• Venue

  Indian Journal of Medical and Paediatric Oncology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/0971-5851.99737PMID 22988350PMCID 3439796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• 8th European Breast Cancer Conference (EBCC-8), Vienna, March 21–24, 2012

  2012influential reference
• Targeting mTOR pathways in human malignancies.

  2012cited by this paper
• Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

  2012influential reference
• BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

  2012cited by this paper
• mTOR as a therapeutic target in patients with gastric cancer

  2012cited by this paper
• Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

  2011cited by this paper
• Novel agents and future directions for refractory breast cancer.

  2011cited by this paper
• PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC).

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011influential reference
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010cited by this paper
• Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

  2010cited by this paper
• mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation

  2010cited by this paper
• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

  2009cited by this paper
• Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer

  2006cited by this paper
• Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

  2004cited by this paper
• World Cancer Report

  2003cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

  1975cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

  1975cited by this paper

• Influence of XGnP as additives on properties of vegetable oil nanolubricant for machining process

  2018cites this paper